Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pertti J Neuvonen

Showing results (51-60 of 192) with videos related to

Pageof 20
Sort By:
Clinical Pharmacology and Therapeutics|August 9, 2005
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolitesJanne T Backman, Harri Luurila, Mikko Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|September 10, 2011
Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beingsXiaoqiang Xiang, Janne T Backman, Pertti J Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|October 26, 2011
No antidotal effect of intravenous lipid emulsion in experimental amitriptyline intoxication despite significant entrapment of amitriptylineErik Litonius, Tomohisa Niiya, Pertti J Neuvonen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2011
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil dosesJohanna Honkalammi, Mikko Niemi, Pertti J Neuvonen, et al.
Clinical Pharmacology and Therapeutics|May 19, 2005
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|July 27, 2006
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitorsTiina Jaakkola, Jouko Laitila, Pertti J Neuvonen, et al.
Pharmacogenetics and Genomics|November 17, 2006
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidMarja K Pasanen, Mikko Neuvonen, Pertti J Neuvonen, et al.
Pharmacogenetics and Genomics|October 16, 2008
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideAnnikka Kalliokoski, Janne T Backman, Pertti J Neuvonen, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearanceCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|January 30, 2004
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjectsCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.
Pageof 20

Showing results (51-60 of 192) with videos related to

Sort By:
Pageof 20
Clinical Pharmacology and Therapeutics|August 9, 2005
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolitesJanne T Backman, Harri Luurila, Mikko Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|September 10, 2011
Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beingsXiaoqiang Xiang, Janne T Backman, Pertti J Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|October 26, 2011
No antidotal effect of intravenous lipid emulsion in experimental amitriptyline intoxication despite significant entrapment of amitriptylineErik Litonius, Tomohisa Niiya, Pertti J Neuvonen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2011
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil dosesJohanna Honkalammi, Mikko Niemi, Pertti J Neuvonen, et al.
Clinical Pharmacology and Therapeutics|May 19, 2005
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.
Basic & Clinical Pharmacology & Toxicology|July 27, 2006
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitorsTiina Jaakkola, Jouko Laitila, Pertti J Neuvonen, et al.
Pharmacogenetics and Genomics|November 17, 2006
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidMarja K Pasanen, Mikko Neuvonen, Pertti J Neuvonen, et al.
Pharmacogenetics and Genomics|October 16, 2008
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideAnnikka Kalliokoski, Janne T Backman, Pertti J Neuvonen, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearanceCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.
British Journal of Clinical Pharmacology|January 30, 2004
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjectsCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.
Pageof 20